Literature DB >> 2451968

Dihydroergotamine and the thromboprophylactic effect of dextran 70 in emergency hip surgery.

M Rørbaek-Madsen1, B W Jakobsen, J Pedersen, B Sørensen.   

Abstract

In a prospective randomized controlled trial treatment with a combination of dextran 70 and dihydroergotamine (DHE) was compared with the administration of dextran 70 alone as prophylaxis against postoperative thrombo-embolic complications in emergency hip surgery. Forty-five consecutive patients with a fractured hip entered the study. Twenty-one were randomized to prophylactic treatment with dextran 70 (group 1) and twenty-four patients received dextran 70 and DHE (group 2). Both regimens were initiated pre-operatively and the surgical and postoperative procedures were the same in the two groups. On the first and fourth postoperative day, Tc-plasmin scintigraphy of the lower extremities and pulmonary ventilation/perfusion scintigraphy were performed to detect any deep vein thrombosis (DVT) and/or pulmonary emboli. A total of 19 per cent of group 1 patients developed DVT and so did 25 per cent in group 2; this difference was not statistically significant. Of the detected DVT, 60 per cent were subclinical, and 7 per cent of the patients had minor pulmonary emboli, all of which were symptomless. No therapeutic difference could be demonstrated between the two regimens. A recent report claiming that adding DHE to the prophylactic administration of dextran 70 considerably reduces the incidence of postoperative DVT in emergency hip surgery is questioned.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451968     DOI: 10.1002/bjs.1800750423

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  1 in total

1.  Prevention of deep vein thrombosis in patients with hip fractures: low molecular weight heparin versus dextran.

Authors:  D Oertli; P Hess; M Durig; U Laffer; R Fridrich; K Jaeger; R Kaufmann; F Harder
Journal:  World J Surg       Date:  1992 Sep-Oct       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.